Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS. Br J Haematol 2025 Sep;207(3):1011-1018

Date

07/23/2025

Pubmed ID

40693472

Pubmed Central ID

PMC12705125

DOI

10.1111/bjh.70020

Scopus ID

2-s2.0-105011357932 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a pivotal part of the treatment algorithm for large B-cell lymphoma (LBCL) in the second- and third-line settings based on numerous clinical trials. However, these studies included very few patients with a diagnosis of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) and it is unclear if outcomes are similar to those observed with more common LBCL histologies. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we identified 111 HGBCL-NOS patients who received CAR-T therapy. The cytokine release syndrome (CRS) rate was 74% (7.7% grade 3+), median onset was 4 days (1-17) and immune effector cell-associated neurotoxicity syndrome rate was 45.2% (22.6% grade 3+), median onset was 7 days (1-17). At 2 years post-CAR-T infusion, the probability of overall survival and progression-free survival were 41.6% and 28.7% respectively. The 2-year non-relapse mortality and relapse/progression were 3.1% (95% confidence interval [CI]: 0.6-7.6) and 68.1% (95% CI: 57.9-77.6) respectively. Our analysis illustrates that patients with HGBCL-NOS represent a particularly difficult group to treat, even with CAR-T therapy. We observed that one third of patients achieved a durable response; however, the overall results were less favourable, with lower overall response rate, overall survival and progression-free survival as compared to published reports on LBCL.

Author List

Hossain NM, Ahn KW, Patel J, Lian Q, Bilal Abid M, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF

Authors

Kwang Woo Ahn PhD Director, Professor in the Data Science Institute department at Medical College of Wisconsin
Mehdi Hamadani MBBS Professor in the Medicine department at Medical College of Wisconsin
Jinal K. Patel Biostatistician II in the Center for International Blood and Marrow Transplant Research department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Female
Humans
Immunotherapy, Adoptive
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Registries
Young Adult